Role of glycogen synthase kinase-3βin pathogenesis and treatment of bipolar disorder:a review
10.3867/j.issn.1000-3002.2016.04.010
- VernacularTitle:糖原合成酶激酶-3β在双相情感性精神障碍发病与治疗中的作用研究进展
- Author:
Ying CUI
;
Rui XUE
;
Youzhi ZHANG
;
Hao HONG
- Publication Type:Journal Article
- Keywords:
bipolar disorder;
glycogen synthase kinase-3;
target;
lithium;
little molecule inhibitors
- From:
Chinese Journal of Pharmacology and Toxicology
2016;30(4):362-368
- CountryChina
- Language:Chinese
-
Abstract:
Bipolar disorder(BD)is a serious mood disorder with high prevalence,morbidity and mortality rates. Glycogen synthase kinase-3β(GSK-3β) is a multifunctional serine/threonine protein kinase that is generally located in eukaryotic cells with such functions as the adjustment of the synthe?sis of glycogen metabolism,cell proliferation and differentiation and gene expression. It is involved in multiple signaling pathways and regulates cell signaling proteins,structural proteins and transcription factors through phosphorylation,affecting the survival of the neurons and plasticity. According to gene poly?morphism and clinical studies,GSK-3β may be associated with BD. As a GSK-3β inhibitor,lithium is an effective BD therapeutic drug,and the small molecule inhibitor targeting GSK-3βis also a hotspot of BD treatment. GSK-3βmay be a potential target in the treatment of BD.
